Related Experiment Video
Updated: May 29, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Experimental evolution reveals adaptive pathways to reduced antibiotic susceptibility in Pseudomonas aeruginosa
Fauve Vergauwe1, Andrea Sass1, Abhinav Madduri1
1Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.
Abstract:
In the present study, we used an experimental evolution approach to investigate how reduced antibiotic susceptibility develops in biofilms formed by Pseudomonas aeruginosa when they are exposed to the clinically relevant antibiotics tobramycin and meropenem. Two biofilm model systems were used, one mimicking surface-attached biofilms (multiple independent P. aeruginosa lineages originating from P. aeruginosa AA2-1 and maintained for 4-10 cycles) and one mimicking biofilm aggregates in cystic fibrosis sputum (multiple independent P. aeruginosa lineages originating from 6 different reference strains and maintained for 15 cycles). Whole-genome sequencing of evolved populations revealed both known and previously unknown genetic adaptations that reduce antibiotic susceptibility. While reduced susceptibility to meropenem commonly arose from mutations in oprD, we also identified a role for irlR. The development of reduced susceptibility towards tobramycin was more complex, with mutations in fusA1, anr, ccoQ1, ptsP, phoQ and nppA1A2BCD associated with adaptation to this antibiotic. Our findings underscore the multifaceted strategies employed by P. aeruginosa to withstand antibiotic pressure in biofilms.
Related Concept Videos
Evolution of New Traits in Microbes
Gene Regulation in Microbial Communities: Quorum Sensing
Mechanism of Antibiotic Resistance in MRSA
Development of Antibiotic Resistance
Biofilms
Transduction

